Drug intelligence / Profile preview

hyoscine butylbromide + paracetamol

Development stage
Phase 2
Lead developer
Boehringer Ingelheim
Modality
Small Molecules
Administration
Oral
01

Overview

**Hyoscine butylbromide + paracetamol** is a fixed-dose combination drug consisting of hyoscine butylbromide (an antispasmodic agent) and paracetamol (an analgesic and antipyretic). Hyoscine butylbromide acts by blocking muscarinic acetylcholine receptors (M3 receptor subtype predominantly) in smooth muscle of the gastrointestinal, biliary, urinary, and female genital tracts, leading to muscle relaxation and relief of spasms. Paracetamol acts centrally by inhibiting prostaglandin synthesis, resulting in analgesic and antipyretic effects. The combination is used for the symptomatic treatment of spasmodic abdominal, biliary, genitourinary, and menstrual pain, where it provides both relief from pain (paracetamol) and reduction of muscle spasm (hyoscine butylbromide)[1][3][4][5]. Major side effects include dry mouth, constipation, blurred vision, and slow heart rate[3][4]. Overdose may cause severe hepatotoxicity due to paracetamol and anticholinergic toxicity due to hyoscine butylbromide.

Brand names
Buscogast PLUSBuscopan VenusDolokind SpasDolokind Spas RFBelicBuscomide PBuscodac PExospas PlusGastreco PMusckan Plus
Other names
hyoscine butylbromide + paracetamolhyoscine-N-butylbromide + paracetamol
02

Targets

M1 (Muscarinic acetylcholine receptor M1)CHRM2 (M2)COXCHRM3 (M3)

Beyond the preview

Go deeper on hyoscine butylbromide + paracetamol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on hyoscine butylbromide + paracetamol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call